

This item is the archived peer-reviewed author-version of:

The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without Pegylated Interferon : a Belgian experience

Reference:

Bielen Rob, Moreno Christophe, Van Vlierberghe Hans, Bourgeois Stefan, Mulkay Jean-Pierre, Vanwolleghem Thomas, Verlinden Wim, Brixco Christian, Decaestecker Jochen, De Galocsy Chantal,- The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without Pegylated Interferon : a Belgian experience
Journal of viral hepatitis - ISSN 1352-0504 - 24:11(2017), p. 976-981
Full text (Publisher's DOI): <https://doi.org/10.1111/JVH.12726>
To cite this reference: <http://hdl.handle.net/10067/1429250151162165141>

The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without Pegylated Interferon: A Belgian experience.

Bielen Rob, MD^{1,2}, Moreno Christophe, MD, PhD³, Van Vlierberghe Hans, MD, PhD⁴, Bourgeois Stefan, MD⁵, Mulkay Jean-Pierre, MD⁶, Vanwollegem Thomas, MD, PhD⁷, Verlinden Wim, MD⁷, Brixco Christian, MD⁸, Decaestecker Jochen, MD^{9,10}, De Galocsy Chantal, MD¹¹, Janssens Filip, MD^{10,12}, Van Overbeke Lode, MD¹³, Van Steenkiste Christophe, MD, PhD^{4,14}, D'Heygere Francois, MD^{10,15}, Cool Mike, MD^{10,16}, Wuyckens Katrien^{1,2}, Nevens Frederik¹⁰, and Robaey Geert^{1,2,10}

1. Faculty of Medicine and Life sciences, Hasselt University, Hasselt, Belgium.
2. Department of Gastro-Enterology and Hepatology, Ziekenhuis-Oost Limburg, Genk, Belgium.
3. Department of Gastro-Enterology and Hepatopancreatology, Erasme Hospital, Brussels, Belgium.
4. Department of Hepatology and Gastro-Enterology, University Hospitals Gent, Gent, Belgium.
5. Department of Gastro-Enterology and Hepatology, ZNA Stuivenberg, Antwerp, Belgium.
6. Department of Gastro-Enterology and Hepatology, Hôpital Saint-Pierre, Brussels, Belgium.
7. Department of Gastro-Enterology and Hepatology, Antwerp University Hospital, Edegem, Belgium.
8. Department of Gastroenterology and Digestive Oncology, CHR Citadelle, Liège, Belgium
9. Department of Gastro-Enterology and Hepatology, AZ Delta, Roeselare, Belgium.
10. Department of Gastro-Enterology and Hepatology, University Hospitals KULeuven, Leuven, Belgium.
11. Department of Gastro-Enterology and Hepatology, Hôpital HIS Bracops, Anderlecht, Brussels, Belgium.
12. Department of Gastro-Enterology and Hepatology, Jessa Hospital, Hasselt, Belgium.
13. Department of Gastro-Enterology and Hepatology, AZ Sint Maarten, Mechelen, Belgium.
14. Department of Gastro-Enterology and Hepatology, AZ Maria Middelaes, Gent, Belgium
15. Department of Gastro-Enterology and Hepatology, AZ Groeninge, Kortrijk, Belgium.
16. Department of Gastro-Enterology and Hepatology, AZ Damiaan, Oostende, Belgium.

Corresponding author: Bielen Rob
E-mail: bielenrob@gmail.com
Phone: +3289/321560
Address: Schiepse Bos 6, 3600 Genk

ABSTRACT

Introduction

Recently, concerns were raised of high rates of HCC recurrence in patients treated with direct acting antivirals (DAA) for hepatitis C infection. We investigated the HCC occurrence and recurrence rates within six months after treatment with DAA with or without Pegylated Interferon (PEG-IFN) in real life.

Methods and materials

This is a retrospective, multicenter cohort trial, executed in 15 hospitals distributed across Belgium. Populations were matched based on fibrosis score (Metavir F3-F4). Patients with a Child-Pugh score \geq B were excluded. In total, 567 patients were included, of whom 77 were treated with PEG-IFN+DAA between 2008 and 2013 and 490 with DAA without PEG-IFN between 2013 and 2015.

Results

Patients treated with PEG-IFN+DAA (53 ± 9 y) were younger than patients treated with DAA without PEG-IFN (59 ± 12 y) ($p=0.001$). 47% of patients treated with PEG-IFN+DAA were in the F4 stage versus 67% of patients treated with DAA without PEG-IFN ($p=0.001$). Screening was inadequate in 20% of both patient groups ($p=0.664$). The early occurrence rate of HCC was 1.7 % and 1.1% in patients treated with DAA with and without PEG-IFN respectively ($p=0.540$). The early recurrence rate was 0% in patients treated with PEG-IFN+DAA, and 15.0% in patients treated with DAA without PEG-IFN ($p=0.857$).

Conclusion

There is no difference in early occurrence of new HCC between patients treated with DAA with and without PEG-IFN. We did observe a high early recurrence rate of HCC in patients treated

with DAA without PEG-IFN. However, these patients were at baseline more at risk for HCC. Finally, in 20% screening for HCC was inadequate.

KEYWORDS

Direct acting antiviral therapy, hepatocellular carcinoma, hepatitis C, pegylated interferon

INTRODUCTION

Patients with cirrhosis whether or not caused by hepatitis C viral infection (HCV) are at risk for development of hepatocellular carcinoma (HCC).(1, 2) Multiple studies have provided evidence that achieving a sustained viral response (SVR) is associated with a reduced risk of HCC.(3-11) Nevertheless, the risk of HCC persists also after SVR and continued monitoring is necessary.(9) Especially patients with cirrhosis, older patients and patients with diabetes, the risk of HCC is estimated to be higher.(9, 12, 13)

The introduction of direct acting antiviral therapy (DAA) has revolutionized HCV therapy these last years.(14-17) These regimens are highly effective and with the arrival of new pan-genotypic regimens in the near future, nearly 100% of the patients can be cured with even more simplified regimens.(18-21) However, caution has been raised for high rates of HCC occurrence and recurrence in patients treated with DAA.(22-25) This heightened the discussion regarding the use of DAA in high-risk patients.(26, 27) However, a retrospective study of three distinct cohorts (HEPATHER-, CirVir- and CUPILT-cohort) of 660 patients in total of whom 516 received DAA therapy, did not report an increased risk of HCC recurrence after DAA treatment.(28)

Therefore, the evidence is still unclear whether there is a real increased risk of HCC after DAA treatment. We have performed a retrospective analysis of patients treated with DAA with and without pegylated interferon (PEG-IFN) in order to further investigate the link between HCC recurrence or occurrence and DAA therapy.

METHODOLOGY

Study Design

We performed a national, retrospective cohort study in 15 hospitals, distributed across Belgium. Data were available from two studies which used the same methodology, focusing on the outcome of DAA with and without PEG-IFN in HCV infected PWID vs non-PWID.(29, 30) Data were collected from the medical patient files.

From the first study, all patients treated with PEG-IFN + ribavirin + telaprevir or boceprevir with a fibrosis score of a Metavir-score of F3/F4 were included. Data were collected between between 2008 and 2013 in 11 hospitals. From the second study, all patients treated with simeprevir + sofosbuvir ± ribavirin, daclatasvir + sofosbuvir ± ribavirin or ombitasvir/paritaprevir ritonavir – dasabuvir ± ribavirin were included. As the Belgian reimbursement criteria were applicable on all these patients, this cohort existed of patients with F3-F4 fibrosis only. Patients with child-pugh B and C cirrhosis were excluded. Data were collected between December 2013 and December 2015 in 15 hospitals.

Endpoints of study

The main objective of this trial was to compare the occurrence and recurrence rates of HCC in patients treated with DAA with and without PEG-IFN. As a secondary objective, we analyzed the percentage of patients who have received radiological follow up within six months after DAA therapy.

Study population

In total, 567 patients were included in this study: 77 patients were treated with DAA and PEG-IFN and 490 were treated with DAA alone. From the patients treated with PEG-IFN, 55.8% (n=43/77) were treated with peginterferon + ribavirin + telaprevir, and 44.2% (n=34/77) were treated with peginterferon + ribavirin + boceprevir. From the patients treated with DAA, 56.1%

(n=275/490) patients were treated with simeprevir + sofosbuvir ± ribavirin, 35.1% (n=172/490) with daclatasvir + sofosbuvir ± ribavirin and 8.8% (n=43/490) with ombitasvir/paritaprevir ritonavir – dasabuvir.

Statistical analysis

Descriptive statistics of patient characteristics are presented: for continuous variables, means and standard deviation, for categorical variables proportions and percentage are given. To compare patient groups, regression methodology was used for continuous variables (such as age and BMI), and Chi-square test for categorical variables (such as fibrosis score, treatment completion). A P-value <0.05 was considered statistically significant.

RESULTS

Baseline characteristics

Patient characteristics are described in Table 1. Patients treated with DAA without PEG-IFN were significantly older and were more often in a compensated cirrhotic stage. They had a different genotype distribution as therapy with PEG-IFN + telaprevir or boceprevir was only reimbursed for genotype 1 patients in Belgium. 51/77 patients treated with PEG-IFN + DAA (66.2%) reached SVR versus 452/479 (94.4%) of the patients treated with DAA without PEG-IFN.

The characteristics of HCC staging and treatment are described in Table 2. Most patients had a BCLC stage A score, and the median follow time between the treatment for HCC and start of HCV treatment was 12 months. Data of the follow-up time were prone to large outliers of patients in follow-up for more than 10 years. 17 patients had follow up of less than 1 year.

Results of follow-up:

The results of follow-up for HCC are visualized in figure 1. In both groups, 80% of patients were screened for HCC by radiological follow-up at least 6 months after the end of treatment for HCV. There was a low rate of HCC occurrence within six months after treatment of 1.1% (n=4/355) in the group treated with DAA and 1.7% (n= 1/59) in the group treated with PEG-IFN + DAA. HCC recurrence however was high in the group treated with DAA without PEG-IFN: 15% (n=6/40).

Characteristics of the patients with HCC recurrence and HCC occurrence are provided respectively in Table 3 and 4. Patients with HCC in the patient history (64 ± 9 y) were clearly older than patients without HCC in their history (58 ± 12 y) ($p=0.001$). Both patients with HCC recurrence and occurrence had a lower rate of SVR. However, this was biased as 4/5 patients who did not reach SVR in these patient groups actually developed HCC during the DAA treatment. This was a reason to stop treatment in these patients. Furthermore, patients with a HCC recurrence, were treated by liver resection (LR) or radiofrequency ablation (RFA) for their primary HCC. This differs significantly from the patients without recurrence: 22 of these patients were treated by a liver transplantation and no patients who had a liver transplant had a recurrence.

DISCUSSION

Due to the development of DAA, our ability to treat HCV infected patients has increased significantly, and more difficult to treat patients can be cured.(18, 21, 31, 32) Earlier trials in the interferon era have provided evidence that reaching sustained viral response (SVR) significantly improves patient outcome, with less development of decompensated cirrhosis and HCC.(3-11) However, this has not been shown for patients treated with DAA, as long-term follow-up is not yet available for these patients. Recently, questions were raised regarding higher than expected recurrence rates of HCC in patients treated with DAA.(22, 23) This conclusion was not confirmed in a retrospective evaluation of patients with HCC in three large cohorts.(28) Furthermore, not only recurrence rates were estimated to be higher, but two more trials warned for higher than expected occurrence rates.(24, 25)

We investigated the occurrence and recurrence rates in a large, multicenter, real-life cohort. To compare this to the interferon era, only patients with a fibrosis stage of F3 or F4 (Child-Pugh A) were included. This was based on the reimbursement criteria for DAA in Belgium, and on the treatment paradigm in the interferon era to not treat patients with advanced liver disease.

In our cohort, we could not find higher than expected early occurrence rates of HCC in patients treated with DAA without PEG-IFN (1.1%; n=4/355) vs. people treated with PEG-IFN + DAA (1.7%; n=1/59). These rates were comparable to the estimated 1%/year frequency of HCC in patients with SVR treated with PEG/IFN and ribavirin dual therapy.(33-36)

We did find a high recurrence rate of 15.0% (n=6/41) six months after treatment with DAA without PEG-IFN. We could not compare this to the cohort of patients treated with PEG-IFN + DAA, as only 1 patient was treated who had a HCC in the history. In our cohort, we found that patients with a HCC recurrence also had a lower SVR rate, but this was due to development of HCC even during treatment. This was the reason to stop treatment in a palliative setting for two

out of three patients. Importantly, only patients treated by LR or RFA of the primary HCC developed recurrence, whereas patients with a liver transplantation did not. Thus 33.3% (3/9) of patients treated with LR had a recurrence and also 33.3% (3/9) of the patients treated with RFA. The time interval from treatment of HCC to treatment of HCV was 10 ± 9 months in the group treated by LR (after removal of one statistical outlier with an interval of 247 months), versus 14 ± 11 months in the group treated by RFA. The time to recurrence interval was 17 ± 12 months in the group treated by LR and 25 ± 4 months in the group treated by RFA. Early HCC recurrence (<2years) complicates 26-50% of the patients treated by LR and 2-18% of the patients treated by RFA.(37-41) Thus, although we found a high early recurrence rate after DAA treatment, these rates are comparable to the findings of the outcome of HCC recurrence after LR or RFA after 24 months of follow-up. Therefore, we cannot state that there is a direct effect of DAA treatment to the HCC recurrence rates in our cohort.

Nevertheless, HCC occurrence or recurrence remains a possibility, therefore clinicians must remain vigilant, also after achieving SVR. This was important in the interferon-era, and will remain important in patients treated with DAA.(33-36). In this real-life cohort, follow up rates were not ideal, as 20% of the people are not screened by radiographic (ultrasound/CT or MRI) analysis at least six months after the end of treatment. Therefore, it is imperative to inform clinicians and patients that a risk of developing HCC remains even after the cure of HCC, and regular follow up is necessary.

CONCLUSION

There is no difference in early occurrence of new HCC between patients treated with DAA with and without PEG-IFN. We did observe a high early recurrence rate of HCC in patients treated with DAA without PEG-IFN. However, recurrence was only seen in patients treated by LR and RFA, and recurrence rates were similar to the rates in patients treated with these treatments after 24 months. In 20%, screening for HCC was inadequate. More efforts are necessary as we need to remain vigilant when treating high risk patients.

ACKNOWLEDGEMENTS

This study is part of the ‘Limburg Clinical Research Program’ (LCRP), supported by the foundation Limburg Sterk Merk, province of Limburg, Flemish government, Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital. The authors state that there are no conflicts of interest.

REFERENCES

1. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. *Hepatology*. 1998;28(6):1687-95.
2. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. *Gut*. 2000;47(1):131-6.
3. Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. *World J Gastroenterol*. 2007;13(42):5648-53.
4. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. *Hepatology*. 2007;46(5):1350-6.
5. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. *J Hepatol*. 2010;52(5):652-7.
6. Hasegawa E, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, et al. Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2. *Hepatol Res*. 2007;37(10):793-800.
7. Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. *J Viral Hepat*. 2006;13(6):409-14.
8. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. *Hepatology*. 2010;52(3):833-44.
9. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA*. 2012;308(24):2584-93.
10. Velosa J, Serejo F, Marinho R, Nunes J, Gloria H. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. *Dig Dis Sci*. 2011;56(6):1853-61.
11. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. *Ann Intern Med*. 2013;158(5 Pt 1):329-37.
12. Chang KC, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH, et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. *J Antimicrob Chemother*. 2012;67(11):2766-72.
13. Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. *Hepatology*. 2013;57(3):964-73.
14. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. *Lancet*. 2014;384(9956):1756-65.
15. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. *N Engl J Med*. 2014;370(3):211-21.
16. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. *N Engl J Med*. 2014;370(20):1879-88.
17. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. *N Engl J Med*. 2014;370(17):1594-603.

18. Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. *N Engl J Med.* 2015;373(27):2618-28.
19. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. *N Engl J Med.* 2015;373(27):2599-607.
20. Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. *N Engl J Med.* 2015;373(27):2608-17.
21. Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, et al. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. *Gastroenterology.* 2016;151(4):651-9 e1.
22. Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. *J Hepatol.* 2016;65(4):719-26.
23. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. *J Hepatol.* 2016;65(4):727-33.
24. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. *J Hepatol.* 2016;65(4):856-8.
25. Cardoso H, Vale AM, Rodrigues S, Goncalves R, Albuquerque A, Pereira P, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. *J Hepatol.* 2016;65(5):1070-1.
26. Camma C, Cabibbo G, Craxi A. Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. *J Hepatol.* 2016;65(4):861-2.
27. Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. *J Hepatol.* 2016;65(4):862-4.
28. stanislas.pol@aphp.fr AcsgohcEa. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. *J Hepatol.* 2016;65(4):734-40.
29. Arain A, Bourgeois S, de Galocsy C, Henrion J, Deltenre P, d'Heygere F, et al. Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs. *J Med Virol.* 2015.
30. Bielen R MC, Van Vlierberghe H, Bourgeois S, Mulkay JP, Franque S, Verlinden W, Brixko C, Decaestecker J, De Galocsy C, Janssens F, Cool M, Van Overbeke L, Van Steenkiste S, D'Heygere F, Cools W, Nevens F, Robaey G. Belgian Experience with Direct Acting Antivirals in People Who Inject Drugs [abstract]. *Hepatology.* 2016;60(4suppl. 1):178A.
31. Reddy KR, Bourliere M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. *Hepatology.* 2015;62(1):79-86.
32. Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, et al. Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis. *Hepatology.* 2015;62(3):715-25.
33. van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. *JAMA.* 2014;312(18):1927-8.
34. Rutter K, Stattemayer AF, Beinhardt S, Scherzer TM, Steindl-Munda P, Trauner M, et al. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. *Aliment Pharmacol Ther.* 2015;41(6):521-31.

35. Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, Conte E, et al. Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. *Gastroenterology*. 2016;151(1):130-9 e2.
36. Lu M, Li J, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, et al. Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma. *J Viral Hepat*. 2016;23(9):718-29.
37. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. *Ann Surg*. 2006;243(2):229-35.
38. Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, et al. Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? *Ann Surg*. 2002;236(5):602-11.
39. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. *Gastroenterology*. 2008;134(7):1908-16.
40. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. *Gastroenterology*. 2005;129(1):122-30.
41. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. *Hepatology*. 2009;49(2):453-9.

TABLES

Table 1: Differences in patient characteristics between patients treated with DAA with and without PEG-IFN.

	PEG-IFN + DAA (n=77)	DAA (n=490)	p-value
Age (y)	52 ± 9	59 ± 12	0.001
Gender			0.161
- male	55 (71.4%)	307 (62.7%)	
- female	22 (28.6%)	183 (37.3%)	
BMI (kg/m²)	27.2 ± 4.6	26.3 ± 4.5	0.169
Comorbidity			
- Diabetes	14/76 (18.4%)	94/490 (19.2%)	0.878
- Renal insufficiency	6/73 (8.2%)	34/490 (6.9%)	0.629
- Psychiatric comorbidity	17/77 (22.1%)	129/485 (26.6%)	0.485
- Liver transplantation	3/73 (4.1%)	33/490 (6.7%)	0.392
Substance abuse			
- Ethyl	16/75 (21.3%)	61/490 (12.4%)	0.046
- Injection drug use	27/77 (35.1%)	100/490 (20.4%)	0.008
HBV coinfection	1/72 (1.4%)	1/403 (0.2%)	0.280
HIV coinfection	4/76 (5.3%)	35/416 (8.4%)	0.489
HCC	1/77 (1.3%)	41/490 (8.4%)	0.031
Treatment experienced	41/77 (55.8%)	285/487 (58.5%)	0.710
HCV Genotype			0.001
- 1a	29/76 (38.2%)	97/489 (19.8%)	
- 1b	42/76 (55.3%)	234/489 (47.9%)	
- 1 (other)	5/76 (6.6%)	11/489 (2.2%)	
- 2	-	-	
- 3	-	69/489 (14.1%)	
- 4	-	72/489 (14.7%)	
- 5	-	2/489 (0.4%)	
- 6	-	-	
- Mixed	-	4/489 (0.8%)	
Viral load (IU/ml)	2.225.788 ± 2.242.795	2.010.473 ± 2.167.505	0.381
Fibrosis stage			0.001
- F3	41/77 (53.2%)	160/486 (32.9%)	
- F4 (Child-Pugh A)	36/77 (46.8%)	326/486 (67.1%)	
SVR	51/77 (66.2%)	452/479 (94.4%)	0.001

PEG-IFN: pegylated interferon; DAA: direct acting antiviral therapy; BMI: body mass index; Psychiatric comorbidity: history of depression, psychosis, anxiety or schizophrenia; Ethyl: > 2-3 alcoholic beverages per day; Injection drug use: patients who have ever injected drugs; HCV: hepatitis C viral infection. HBV: hepatitis B viral infection; HIV: human immunodeficiency virus. HCC: history of hepatocellular carcinoma. Fibrosis stage: according to Metavir criteria. If F4 stage: Child-Pugh classification was used. SVR: sustained viral response.

Table 2: HCC characteristics before HCV treatment

	PEG-IFN + DAA (n=1)	DAA (n=41)
BCLC staging score		
- 0	-	1/41 (2.4%)
- A	1/1 (100%)	33/41 (81.0%)
- B	-	7/41 (17.1%)
Volume HCC (cm)	1.9	3.31 ± 3.17
Number of tumors (n)	1	1.53 ± 0.76
Alpha-fetoprotein level (IU/ml)	14.3	45.6 ± 69.7
Treatment		
- Liver transplantation	1/1 (100%)	21/41 (51.2%)
- Resection	-	10/41 (24.4%)
- RFA	-	9/41 (22.0%)
- TACE	-	1/41 (2.4%)
Mean time between HCC treatment and start HCV treatment (months) (mean ± SD; median)	11 months	33 months ± 47; 12

BCLC= Barcelona clinic liver cancer (group); Volume HCC: largest diameter of largest nodule; number of tumors: number of HCC localizations in the liver; alpha-fetoprotein level: level of alpha-fetoprotein before treatment for HCC; RFA= radio-frequency ablation; TACE= trans-arterial chemo-embolization.

Table 3: Characteristics of patients with HCC recurrence vs patients without HCC recurrence 6 months after DAA treatment.

	HCC recurrence (n=6)	Non-HCC recurrence (n=35)	P-value
Age (y)	65 ± 12	64 ± 9	0.868
BMI (kg/m²)	28.1 ± 5.2	25.9 ± 4.3	0.362
Diabetes	4/6 (66.7%)	15/35 (42.9%)	0.512
Fibrosis stage			0.559
- F3	1/6 (16.7%)	8/32 (25.0%)	
- F4 (Child-Pugh A)	5/6 (83.3%)	24/32 (75.0%)	
SVR	3/6 (50.0%)	33/35 (94.3%)	0.017
BCLC staging			0.914
- 0	-	1/35 (2.9%)	
- A	5/6 (83.3%)	28/35 (80.0%)	
- B	1/6 (16.7%)	6/35 (17.1%)	
Volume (cm)	2.9 ± 1.3	3.5 ± 3.7	0.661
Number of tumors (n)	1.17 ± 0.4	2.0 ± 2.11	0.346
Alpha-fetoprotein level (IU/ml)	63.32 ± 89.73	43.40 ± 68.02	0.582
Time interval (months) (mean ± SD; median)	16 ± 10; 17	35 ± 50; 12	0.381
Treatment HCC			0.009
- Liver transplantation	-	22/35 (62.9%)	
- Resection	3/6 (50.0%)	6/35 (17.1%)	
- RFA	3/6 (50.0%)	6/35 (17.1%)	
- TACE	-	1/35 (2.9%)	
Time to recurrence HCC (mean ± SD; median)	21 ± 11; 24	-	

BMI= body mass index; SVR= sustained viral response; BCLC= Barcelona clinic liver cancer (group); Volume HCC: largest diameter of largest nodule; number of tumors: number of HCC localizations in the liver; alpha-fetoprotein level: level of alpha-fetoprotein before treatment for HCC (after removal of outlier of 2321IU/ml in the non-HCC recurrence group); Time interval= time between HCC treatment and start HCV treatment; SD= standard deviation: HCC= hepatocellular carcinoma; RFA= radiofrequent ablation; TACE= transarterial chemo-embolization.


Table 4: Characteristics of patients with HCC occurrence vs patients without HCC occurrence six months after DAA treatment.

	HCC occurrence (n=5)	Non-HCC occurrence (n=409)	P-value
Age (y)	62 ± 9	58 ± 12	0.451
BMI (kg/m²)	31.3 ± 8.9	26.5 ± 4.3	0.365
Diabetes	2/5 (40.0%)	78/408 (19.1%)	0.249
Fibrosis stage			0.449
- F3	1/5 (20.0%)	139/408 (34.1%)	
- F4 (Child-Pugh A)	4/5 (80.0%)	269/408 (65.9%)	
SVR	3/5 (60%)	369/407 (90.7%)	0.076

HCC= hepatocellular carcinoma; BMI= body mass index; SVR= sustained viral response.

FIGURES

Figure 1: Screening, occurrence and recurrence rates of HCC in patients treated with DAA with and without PEG-IFN.



HCC= hepatocellular carcinoma; DAA= direct acting antiviral therapy.